Comorbidity: Anemia and heart failure;Komorbidität: Anämie und Herzinsuffizienz

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 16, 2009, Pages 825-830

  Mahfoud, F ^a   Kindermann, I ^a   Kindermann, M ^a   Ukena, C ^a   Bohm M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; COMORBIDITY; HEART FAILURE; REVIEW; GERMANY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS;

ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; FERRIC ION; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; COMORBIDITY; ERYTHROPOIETIN; FERRIC COMPOUNDS; GERMANY; HEART FAILURE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; PREVALENCE; PROGNOSIS;

EID: 64349121754     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1220238     Document Type: Review

References (50)

1. Al-Ahmad A, Rand WM, Manjunath G et al Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38 (4): 955-962
2. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialy- sis patients. Nephrol Dial Transplant 1998; 13 (5): 1206-1210
3. Anand I, McMurray JJ, Whitmore J et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110 (2): 149-154
4. Anand IS, Kuskowski MA, Rector TS et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005; 112 (8): 1121- 1127
5. Androne AS, Katz SD, Lund L et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107 (2): 226-229
6. Anker SD, Chua TP, Ponikowski P et al. Hormonal changes and catabolic/ anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96 (2): 526-534
7. Anker SD, Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004; 90 (4): 464-470 (Pubitemid 38406929)
8. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299 (8): 914-924
9. Besarab A, Soman S. Anemia management in chronic heart failure: lessons learnt from chronic kidney disease. Kidney Blood Press Res 2005; 28 (5- 6): 363-371
10. Bolger AP, Bartlett FR Penston HS et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48 (6): 1225-1227
11. Deswal A Petersen NJ Feldman AM, Young JB, White BG, Mann DL Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103(16): 2055-2059 (Pubitemid 32373007)
12. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355 (20): 2071-2084
13. Ezekowitz JA, McAlister FA Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003; 107 (2): 223-225
14. Felker GM, Gattis WA, Leimberger JD et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003; 92 (5): 625-628
15. George J, Patal S, Wexler D et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neuro- hormonal and inflammatory markers. Arch Intern Med 2005; 165 (11): 1304-1309
16. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103(13): 1746-1751
17. Go AS, Yang J, Ackerson LM etal. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113 (23): 2713-2723
18. Griffith GC, Stragnell R Levinson DC, Moore FJ, Ware AG. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952; 37 (5): 867-887
19. Hoppe UC. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? ATI-receptor antagonists? Clin Res Cardiol 2007; 96 (4): 196-198
20. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39(11): 1780-1786
21. Kalra PR Bolger AP, Francis DP et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003; 91 (7): 888-891
22. Kazory A, Ross FA. Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol 2009; 53 (8): 639-647
23. Komajda M. Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J Card Fail 2004; 10(1 Suppl): S1-S4
24. Kosiborod M, Smith GL Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med 2003; 114 (2): 112-119
25. Levine B, Kaiman J, Mayer L Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323 (4): 236-241
26. Upton AJ, Johnson MA, Macdonald T, Lieberman MW, Gozal D, Gaston B. S-nitrosothiols signal the ventilatory response to hypoxia. Nature 2001; 413(6852): 171-174
27. Maggioni AP, Opasich C Anand I et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 2005; 11 (2): 91-98
28. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107 (2): 294-299
29. Mitchell JE. Emerging role of anemia in heart failure. Am J Cardiol 2007; 99 (6B): 15D-20D
30. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE).J Am Coll Cardiol 2003; 41 (11): 1933-1939
31. Murphy CL, McMurray JJ. Approaches to the treatment of anaemia in patients with chronic heart failure. Heart Fail Rev 2008; 13 (4): 431-438
32. Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol 2003; 23 (5): 287-293
33. Nanas JN, Matsouka C, Karageorgopoulos D et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48 (12): 2485- 2489
34. Nixon JV. Left ventricular mural thrombus. Arch Intern Med 1983; 143 (8): 1567-1571
35. Okonko DO, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, obseiver-blinded trial. J Am Coll Cardiol 2008; 51 (2): 103- 112
36. Ponikowski P, Anker SD, Szachniewicz J et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49 (7): 753-762 (Pubitemid 46240705)
37. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52 (19): 1527-1539
38. Schwengel RH, Gottlieb SS, Fisher ML. Protein-energy malnutrition in patients with ischemic and nonischemic dilated cardiomyopathy and congestive heart failure. Am J Cardiol 1994; 73 (12): 908-910
39. Sharma R Francis DP, Pitt B, Poole-Wilson PA Coats AJ Anker SD. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004; 25 (12): 1021-1028
40. Silverberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35(7): 1737-1744
41. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006; 26 (4): 296-306
42. Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37 (7): 1775-1780
43. Singh AK, Szczech L Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355 (20): 2085-2098
44. Smilde TD, Damman KHP et al. Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure. Clin Res Cardiol 2009; 98 (2): 121-129
45. Szachniewicz J Petruk-Kowalczyk J, Majda J et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 2003; 90 (2-3): 303-308
46. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113 (20): 2454-2461
47. Tanner H, Moschovitis G, Kuster GM et al. The prevalence of anemia in chronic heart failure. Int J Cardiol 2002; 86(1): 115-121
48. van der Meer, Voors AA Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44 (1): 63-67
49. van Veldhuisen DJ, Dickstein K, Cohen-Solal A et al. Randomized, double- blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007; 28 (18): 2208-2216
50. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310 (6983): 827-830